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During the second half of the 20th century 
there has been a fl ood of new medical 
technologies that have transformed 
many aspects of clinical practice.  From 
novel pharmaceuticals through to 
developments in bioengineering and 
the new genetics, innovative health 
technologies (IHTs) have had a major 
impact on medical diagnosis and 
therapy (Brown and Webster, 2004). 
However, the process of introducing and 
establishing IHTs involves more than 
simply the discovery or invention of a 
‘technical’ or instrumental solution to a 
clinical problem: before a new medical 
technology can be applied in everyday 
health care it has to undergo some sort 
of testing to ensure that it achieves what 
Stabilising the construct of health related 
quality of life: 
1970-2007
David Armstrong
This paper describes the process by which the construct of health related quality of 
life was stabilised as an important goal of medicine. From its initial rhetorical use in the 
1970s through periods of advocacy and methodological development the construct 
was fi nally stabilised through the appearance and application of formal quality of 
life instruments in medical research and clinical practice. Yet despite the centrality of 
quality of life measurement for modern medicine and its current operationalisation in 
over a thousand questionnaires, the underlying construct remains contested and can 
still be described as a ‘loose concept’.
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it claims to achieve. Indeed, this process 
of technology evaluation has assumed 
greater and greater signifi cance in the 
light of the rapidity of technological 
innovation, the frequent failure of past 
technologies to deliver their promise, 
and the need to apply limited health care 
resources to best effect.
Allocation of health care resources, 
whether at the level of the health care 
system, the clinic or the individual patient, 
has depended on an implicit or explicit 
outcome measure that would show the 
value of the intervention in question. 
Earlier in the 20th century outcomes were 
largely measured in terms of mortality 
or ‘cure’. But then two factors began to 
undermine the value of these traditional 
Science Studies, Vol. 22 (2009) No. 2, 102-115
103
medical criteria. One was the diminishing 
returns in certain areas of therapy. For 
example, new interventions to treat 
many cancers and leukaemia began 
to show smaller and smaller effects on 
longevity. The other was the observation 
that the biological status of the patient 
might not refl ect their subjective status, 
meaning that a patient might be helped 
biologically but report no improvement, 
or conversely, might achieve no biological 
improvement yet report considerable 
subjective betterment. At its most 
salient this was marked by interventions 
that produced improvements in life 
expectancy counter-balanced by 
major decline in patients’ subjective 
sense of well-being. Indeed, post-war 
technological ‘successes’ such as renal 
dialysis and organ transplantation were 
often achieved at considerable personal 
cost to the patient (Le Fanu,1999)
In the 1970s a rhetoric emerged that 
stressed a new goal for medicine, that of 
improving health-related quality of life 
(QoL) (Armstrong and Caldwell, 2002) 
and over the following decade a number 
of existing measure —of disability, of 
mental health, of social functioning 
and of symptoms—were conscripted 
to the task of generating QoL measures 
(Armstrong et al., 2007). Of course this 
process was not achieved overnight. The 
very construct of QoL had to be sold to a 
sceptical profession and creative ways of 
capturing the concept with an empirical 
measure had to be sought. This process 
was a contested one in terms of resistance 
to the idea and competition between 
alternative and competing measures, 
as described below, but following its 
identifi cation and promotion in the 1970s 
QoL has come to dominate thinking about 
health care outcomes. QoL measurement 
has grown from virtually nothing in the 
early 1970s to a vast literature and nearly 
1,000 instruments 35 years later. Some 
indication of the size of the fi eld can be 
established from the number of papers 
in the medical database PubMed that 
address QoL issues (Figure 1) which now 
total almost 100,000 references.
The process of establishing and 
organising this fi eld of endeavour is 
continuing but the stages of development 
so far provide an insight into the way QoL 
Figure 1.  Growth in QoL Publications.
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‘colonised’ modern medicine. By turning 
a vague idea into a measurable ‘fact’ 
QoL made the transition from rhetorical 
concept to hard end-point of clinical 
practice. Further, while the stages of any 
scale development are now formalised 
and well described in methodological 
texts, the wider context of the social 
activity surrounding the creation of new 
instruments can be illustrated by the 
example of QoL. And while the timescale 
for the development of a new instrument 
might be measured in months or years 
the steps from conceptualisation to 
widespread implementation can take 
decades, as this case history illustrates. 
Method
Papers dealing with QoL were identifi ed 
from the PubMed database and a 
random sample of 50 papers was chosen 
from every 5th year starting in 1980. The 
number of papers available in the very 
fi rst period of interest, 1975, was only 36 
so a full census of these papers was taken. 
In total 336 papers were examined for this 
study.
Figure 2. Proportion of different types of QoL publications
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Details of each paper were catalogued. 
This was mainly from the abstract but 
where this was missing or unclear the 
actual paper was examined. Papers 
were initially broadly classifi ed into 
four categories. These were: Outcome 
or Empirical papers that reported QoL 
assessments of particular groups of 
patients; Review papers that collated and 
analysed the empirical data from papers 
reporting outcome data; Methodological 
papers that were concerned with 
further development of measurement 
procedures; and fi nally, Non-empirical or 
discursive papers that did not fi t any of the 
above three categories. The latter, as will 
be shown, were much more important in 
the early years. The distribution of papers 
according to these four groups is shown 
in Figure 2.
Classifi cation of papers was not 
always clear-cut and the changes over 
time suggested in Figure 2 are indicative 
only. They do, however, provide a useful 
framework for mapping the emergence 
of the QoL literature by showing the 
growth and stability of different types of 
paper. This broad picture can be further 
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enriched by considering changes over 
time within the four types of paper.
Finally database searches were also 
made for some of the more signifi cant 
QoL measures to explore the life 
trajectory of individual questionnaires or 
instruments.
Beginnings
The fi rst year investigated in the 5-year 
samples from the PubMed database, 
1975, was at the very beginning of the 
emergence of QoL as a major fi eld of 
study and, as noted, only consisted of 
36 papers in total. The dominant type of 
paper was the Non-empirical variety. The 
period might be seen as belonging to an 
‘advocacy’ phase of development in that 
most papers promoted the value of taking 
QoL seriously as a medical outcome 
even though there were few empirical 
instances of its actual use as a health 
status measure. Indeed, three of the 36 
papers had an explicit educational focus 
as they sought to persuade the reader of 
the importance of QoL.
Explicit advocacy has not been a 
strong genre in medical journals in the 
late 20th century and mainly occurs in 
editorials. Yet of the 30 ‘advocacy’ papers 
identifi ed here only one was an editorial. 
A few papers were simply in the format 
of published lectures but most were 
basic appeals or exhortations to use, 
aim for or value the patient’s QoL as a 
central component of health care. In 
consequence, given the contemporary 
empirical slant of most mainstream 
medical journals this meant that a 
high proportion of those papers were 
published in non-medical, particularly 
nursing (seven articles), or lower profi le 
medical journals.
Of the remaining six papers, fi ve were 
concerned with QoL as an Outcome in 
which empirical fi ndings were reported. 
These included QoL in patients with 
leukaemia, with childhood cancer, 
on haemodialysis and as a result of 
improved housing. This list resonates 
with the medical and social debates 
that underpinned the emergence of 
the concept of QoL in that it echoes 
some of the ‘social indicator’ research 
as well as focuses on diseases given 
‘aggressive’ medical therapy (Armstrong 
and Caldwell, 2002; Le Fanu, 1999). Two 
strategies were pursued in measuring 
QoL. One was to recruit existing measures 
of related concepts to the task. For 
example, one paper examined the effect 
of housing on morale and life satisfaction 
using two existing questionnaires and 
another argued that as ‘sense of security’ 
was an aspect of QoL it was then justifi ed 
to use ‘fear’ as a negative correlate of QoL 
in a secondary data analysis. The other 
strategy was to create new rudimentary 
measures such as assessing whether QoL 
was good, fair or poor supplemented by 
assessments of loss of income and family 
life.
There was only one paper that explicitly 
addressed methodological issues—in this 
case a review of procedures for valuing 
lives. Even so, two of the Non-empirical 
papers discussed the nature of QoL 
which might be considered a conceptual 
precursor to the measurement process.
In summary the 1970s marked the 
birth of health-related QoL as a legitimate 
medical outcome. Mainly, published 
papers were concerned with ‘marketing’ 
the idea of QoL as a goal worth pursuing 
even though at the time ways of measuring 
the concept were few and rudimentary. 
Once the idea was accepted, however, this 
defi cit could be rectifi ed with a surge in 
methodology-driven papers creating and 
validating new instruments and reports 
of their empirical application.
David Armstrong
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The decline of Non-empirical papers
Whereas 90% of papers in 1975 were Non-
empirical rhetorical or opinion pieces, 
fi ve years later the proportion had fallen 
to nearer 50% (28 out of 50). Moreover, 
the content of these papers had begun 
to change: instead of arguments for the 
importance of QoL the agenda was how 
to measure it and apply it. Given this 
focus several of these papers could be 
described as quasi-methodological; they 
did not address measurement issues 
directly but they began the conceptual 
ground-clearance that would enable the 
emergence of formal instruments. The 
involvement of nursing journals that had 
been such a feature of the 1975 literature, 
however, began to decline —a process 
that was speed up during the decade 
such that by the 1990s nursing journals 
contributed only marginally to the QoL 
debates.
The main focus of the Non-
empirical papers remained advocacy 
and persuasion with a wider range of 
medical conditions being described that 
would benefi t from applying QoL as the 
principal outcome of care. But there was 
also a new thread in seven out of the 28 
Non-empirical papers as the recently 
emergent medical ethics or bioethics 
began to engage with the QoL debate (with 
ethical, legal and administrative journals 
provided a good proportion of this type 
of paper) (Callahan, 1973; Jonsen, 1998; 
Martensen, 2001; Rothman, 1991). In life 
and death decisions in particular QoL 
began to fi gure as the reference state for 
ethical judgement.
In 1985 the proportion of Non-
empirical papers held steady at 24 out 
of 50.  An increasing proportion of these 
were in ethics and/or legal journals with 
a declining number in nursing journals. 
Most of these papers remained polemical 
but two new genres can be identifi ed 
as beginning to emerge. The fi rst was 
greater theoretical dissection of QoL (that 
also overlapped with the Methodological 
papers). As new questionnaires were 
devised and QoL ratings for patients’ 
experience accumulated (see below) 
it became necessary to question what 
exactly was being measured: empirical 
developments therefore led to even greater 
scrutiny of conceptual underpinnings. 
The second new genre of papers was an 
increasing emphasis on educating the 
reader about the substantive parts of 
the QoL movement. The latter especially 
signifi ed a more confi dent shift from 
discussing what should happen to what 
was happening.
In the 1990s the proportion of Non-
empirical papers began a rapid decline. 
In 1990, for example, their proportion 
halved to only 28% of that year’s sample. 
Over a third of these were now explicitly 
educational in nature while papers 
concerned with ethical aspects of QoL 
had declined to only two papers. And 
by 1995 Non-empirical papers had 
shrunk to only four (8%). One of these 
concerned ethics, the other three were 
editorials offering an assessment of QoL 
in a particular area, though not formally a 
review paper. In both 2000 and 2005 Non-
empirical papers were down to three 
papers mainly ‘educational/review’ type 
editorials.
Thus some 20 years after the 
appearance of QoL as a concept and 
measure in medicine the discursive 
‘opinion’ piece that had extolled its virtues 
or promoted its uptake had virtually 
come to an end. Given the contemporary 
growth in empirical and methodological 
papers this might be held to mark the end 
of the struggle to get QoL accepted. There 
was now no need to exhort colleagues to 
take an interest in this ‘new’ idea as it was 
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fi rmly established. What it needed next 
was more work on its measurement and 
studies to show its value.
The rise of Outcomes research
Whereas in 1975 only fi ve out of 36 papers 
presented empirical evidence of QoL 
in specifi c clinical populations, by 1980 
fi  fteen papers out of the 50 sampled 
presented QoL as an empirical outcome 
measure. The commonest approach (8 out 
of 15) was simply to describe the QoL in a 
cross-section of patients with a specifi c 
condition. The implicit justifi cation 
seemed to lie in the choice of medical 
conditions which all in some way had 
high impact on QoL. The QoL of patients 
with cystic fi brosis, haemodialysis and 
ileostomy was all believed to be impaired, 
the question was by how much.
Three out of the 15 empirical papers 
reported QoL before and after a medical 
intervention (radiation for prostate 
cancer and mastectomy for breast 
cancer), two compared the impacts 
of different treatments on QoL (renal 
transplant versus dialysis and the QoL of 
volunteers and non-volunteers) and one 
used QoL as an outcome in a randomised 
clinical trial (of cytotoxic drugs versus 
endocrine therapy in breast cancer). The 
way QoL was measured in these empirical 
studies varied widely from use of the 
formal Carlens vitagram index to what 
were described as ‘subjective responses’.
The number of papers addressing 
Outcomes was similar in 1985 with 14 
papers reporting empirical fi ndings. Only 
four papers reported cross-sectional 
measures of QoL in specifi c high salience 
patient populations including paraplegics 
in Nigeria, mental patients in nursing 
homes and severely mobility disabled 
patients. The balance of papers, however, 
had more emphasis on comparisons of 
patient groups including an increase to 
two clinical trials, a review (of parenteral 
nutrition) and a meta-analysis. Two 
comparisons picked up the now familiar 
treatment of renal disease with one of 
dialysis versus transplantation and one of 
haemodialysis versus peritoneal dialysis.
By 1990 Outcome papers had become 
the most common. Most of these provided 
simple descriptions of patient groups 
with various illnesses (spinal cord injury, 
burns, epilepsy, hypertension, cystic 
fi brosis, etc) including two papers which 
examined QoL in dying patients. In 1990 
two papers also appeared that reported 
QoL in individual patients (rather than in 
diagnostic groups): one reported QoL in 
two patients with brain tumours and one 
was a more personal account of the impact 
of a wife’s breast cancer. There were only 
two ‘comparative’ papers (comparing 
QoL in diabetes compared with chronic 
obstructive pulmonary disease and in 
insulin dependent diabetes compared 
with non-insulin dependent) and only 
one trial (in AIDS).
In 1995 a clear half of all papers also fell 
into the Outcomes category but the sub-
types showed signifi cant changes with 
purely descriptive papers less common, 
QoL in HIV and in leukaemia being 
the only two. Studies that compared 
QoL across populations were the main 
replacement for papers that reported the 
QoL of specifi c patient groups, though 
sometimes the difference was not very 
clear as in, for example, comparison of 
the QoL of patients in Texas and New 
York. More typically comparative studies 
involved measurement of QoL before and 
after a medical intervention (two thirds of 
papers in the Outcome category and 30% 
of all papers in the 1995 sample). There 
were a further six papers with an economic 
focus that built on QoL measurement in 
developing cost-effectiveness estimates 
David Armstrong
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particularly through the calculation 
of Quality Adjusted Life Years (QALYs) 
(Williams, 1985) as a mechanism for 
allocation of health resources.
By 2000 almost two thirds of papers 
used QoL as an outcome measure. 
There was a trickle of descriptive papers 
mostly of unusual clinical populations 
or of non-clinical populations, such 
as carers’ responses to hospital 
discharge. Most papers, however, were 
comparative studies, usually evaluations 
of interventions.  Of the latter, four were 
trials, three more than in 1995. There 
were also three studies tracking changes 
in QoL at long-term follow-up of different 
diseases.
The decline in descriptive studies was 
maintained in 2005 (only 6 out of 50). These 
continued exploring QoL in rare diseases 
(eg Systemic Lupus Erythematosis) but 
increasingly emphasised QoL of ‘others’ 
not directly affected by health problems 
such as partners of patients with cancer, 
carers of patients with heart failure and 
siblings of children with cancer. The 
largest group of papers in 2005 involved 
the use of QoL as a clinical endpoint (20 
out of 50).
By 2005 QoL assessments also began to 
be used in experimental medicine, that is, 
studies in which new interventions were 
‘tested’ on individual or small groups of 
patients. There had been earlier reports of 
QoL in individuals but these tended to be 
more anecdotal than methodologically 
rigorous but experimental medicine was 
a new conquest for QoL measurement. 
This type of study had traditionally relied 
on physiological surrogate outcomes to 
test for the signals of therapeutic benefi t 
of a new intervention but the use of QoL 
as an endpoint marked a new departure. 
There were fi ve such papers ranging from 
a report of the impact of an intervention 
on a rare disease in one patient to the 
effect of treatment of postural instability 
in six patients.
Since 1975 the QoL literature had 
been characterised by the major growth 
of studies measuring QoL in defi ned 
clinical and non-clinical populations (a 
development paralleled by the growth 
of useable questionnaire instruments: 
see below). Yet while these research 
studies had grown in number and 
proportion they had also changed in 
design. At the outset the task seemed to 
be to use the QoL measure to confi rm 
that QoL was indeed compromised in 
‘at risk’ populations. This process then 
extended to other clinical populations, 
the publication often being justifi ed by 
the claim that no-one had previously 
examined the QoL of patients with XYZ 
disease. But this genre had a limited life: 
there were only so many clinical groups 
that could have their QoL measured so 
gradually the genre diminished to a trickle 
of papers that offered simple description 
of QoL in increasingly rare disease groups 
or in non-patient populations such as 
carers, spouses and siblings. Thus, just 
as the decline in rhetorical papers might 
be held to mark the end of a phase of 
adoption so might the brief effl orescence 
then virtual disappearance of simple 
descriptive studies mark the ‘arrival’ of 
the new concept.
In contrast the research approach 
that used QoL as an evaluative tool 
has proved more long lasting. At fi rst 
this development was almost an after-
thought to the earlier descriptive studies 
wondering whether the QoL of patients 
with disease X was better or worse 
than patients with disease Y. It was but 
a short step then to incorporate QoL 
measurement into formal evaluations 
of an intervention using either before-
after or comparison group designs. The 
pinnacle of the latter of course was the 
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randomised controlled clinical trial and 
there was a notable increase in use of 
QoL as an endpoint over the period under 
investigation (see Figure 3).
The standardisation of QoL as an 
important measure of clinical outcome 
was also illustrated by the appearance 
of fi ve empirical papers in 2005 that 
used QOL in innovative ways. The fi rst 
examined QoL of staff—an indicator 
that QoL measurement was spreading 
not only to carers, siblings, etc, but also 
to health care professionals. The second 
paper was a study that used QoL as an 
independent predictor variable (for oral 
cancer mortality). All previous empirical 
papers had treated QoL as an outcome 
measure, as a dependent variable. 
The use of QoL as a predictor variable 
implicitly recognised the independent 
existence of the QoL construct. QoL was 
not solely a product of other forces but 
in itself could affect the world. The third 
paper reported using QoL in a clinical 
guideline (for the management of chronic 
obstructive airways disease). Guidelines 
had emerged over the previous decade 
as a means of encoding evidence-based 
medicine and communicating it to health 
professionals. The fact that QoL could be 
a major factor in ‘selling’ the guideline 
advice to health care professionals (‘if this 
treatment is followed then the patient’s 
QoL will be improved’) indicated that 
QoL had become a widely accepted 
clinical outcome.
The fi nal two papers used qualitative 
methods to explore QoL in two settings. 
The history of QoL measurement can be 
crudely characterised as rhetorical work 
around the promotion of the nascent 
concept followed by its stabilisation with 
successive measurement operations 
(using increasingly standardised 
instruments) and the consequent 
accumulation of a vast body of QoL ‘facts’. 
The exploration of QoL in qualitative 
studies suggests recognition that the 
construct itself had been stabilised. It no 
longer needed ‘fi xing’ with an instrument 
that was known to elicit its presence 
and ‘quantity’, rather the search for QoL 
in unstructured ‘talk’ implied that the 
construct could exist and be identifi ed 
independently of any formal instrument.
Figure 3. Citations to trials and QoL
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The accumulation of Reviews
While some of the early Non-empirical 
papers attempted to summarise research 
on QoL in a particular area it was only 
in 1990 that ‘proto-review’ papers began 
to appear. In that year two papers had 
attempted to offer an ‘opinion’ based on 
a review of the existing literature. While 
these ‘reviews’ appeared informal they 
did complement a further six papers (out 
of 50) that claimed to offer a formal review 
of the application of QoL in a particular 
fi eld. These covered the measurement 
of QoL in breast cancer, in rheumatoid 
arthritis, in diabetes, after taking ACE 
inhibitors, erythropoietin for end stage 
renal disease and about the meaning of 
QoL. Five years later, in 1995, there were 
further fi ve review papers; two in 2000 
and three editorial reviews and seven 
systematic reviews in 2005. 
In part the growth of these review 
papers refl ected the emerging evidence-
based medicine paradigm that gave high 
priority to rigorous reviews of existing 
evidence (particularly in the form of 
systematic reviews (Davidoff et al., 
1995)) but in part it also indicated that 
the raw material of papers using QoL 
as an outcome were proliferating. The 
very appearance of these review papers 
indicated the successful accumulation of 
an empirical base for QoL measurement.
The rise and fall of Methodology
In 1980 there were four papers with 
a Methodology fl avour. One of these 
described the development of a 
new subjective health measure (the 
Nottingham Health Profi le), one the 
diffi culty of measuring subjective 
indicators and two examined correlates 
of QoL in an attempt to refi ne what it 
really meant.
In 1985 the proportion of papers 
devoted to methodological issues 
doubled (8 out of 50) not counting 
those Miscellaneous papers that had 
a conceptual focus (one, for example, 
addressed the meaning of enjoyment). 
The methodological papers ranged from 
those developing or proposing new 
measures to those concerned with more 
general issues of bias in questionnaire 
based instruments.
By 1990 a quarter of the papers focused 
on methodological issues. Four of these 
tried to grapple with the conceptual 
nature of QoL, while the rest dealt with 
scale development and methods of 
analysis. There were similar proportions 
in 1995 and 2000. These latter papers 
were dominated by development of 
new questionnaires including their 
psychometric properties but also, in 
2000, two studies reported ‘head-to-head’ 
comparisons of different instruments. 
Discussion of conceptual issues also 
continued with one paper exploring the 
meaning of happiness.
In 2005 there were only fi ve explicitly 
methodological papers, a marked 
reduction from the numbers over the 
previous decade. Three of these reported 
the development of  QoL measures such 
as testing the validity of the Kansas 
City Cardiomyopathy Questionnaire, 
translating an instrument from English 
into Turkish and development of a 
computer based QoL for the deaf. But 
two studies were concerned not with 
developing QoL measurement but with 
using QoL scales as means to test or 
validate other instruments.
The rise of Methods-papers maps 
the growth and consolidation of QoL 
measurement in evaluation research. 
Their proportion increased until 1985, 
held steady until 1995, then began to 
decline. Once the key measurement 
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instruments were established the core 
task shifted from developing them to 
using them. Moreover the more recent 
appearance of methodological studies 
that have tried to validate non-QoL 
measures through their association with 
QoL instruments suggests the increasing 
stability of the latter.
The growth of individual instruments
There are currently over a 1,000 different 
QoL instruments in existence. Most of 
these are disease-specifi c questionnaires 
that can be used to map changes in QoL 
following treatment but many are generic 
instruments that can be used to assess 
QoL across populations irrespective of 
their disease profi les. The latter have 
become particularly important as value-
for-money considerations require health 
care funders to compare the impact of 
different treatments in different diseases.
Figure 4 shows the growth in citations 
of fi ve generic instruments. The SF-36, a 
US originated questionnaire, clearly has 
come to dominate the fi eld of generic 
measures. When compared to growth in 
disease-specifi c instruments, however, 
it shows some relative decline when set 
against citations to all QoL instruments 
(Figure 5). One of the oldest instruments, 
Cantril’s ladder barely survives into the 
new century. The Sickness Impact Profi le 
(SIP) also to some extent pre-dates the 
QoL era as it was originally designated as 
a ‘subjective health measure’ but despite 
its accumulated success it has been 
overtaken by the SF-36 in recent years. Of 
note is the ‘success’ of the Barthel Index 
which was fi rst designed and intended as a 
measure of activities of daily living (ADLs) 
for patients with physical disabilities. As 
ADLs form an important component of 
QoL (Armstrong et al., 2007), and with 
the growth of physical disability of an 
ageing population in Western countries, 
its continuing use probably refl ects its 
original purpose.
Figure 6 shows the relative recent 
strength (with the SIP as comparator) of 
two new types of instrument, economic 
Figure 4. Citation counts showing growth of individual instruments
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and international. The two ‘economic’ 
instruments (the EQ-5D and the Health 
Utilities Index) have been designed for 
easy linkage to a cost tariff so that an 
economic ‘value’ of any QoL state can be 
Figure 5. Citations to QoL instruments
Figure 6. Growth of ‘economic’ and ‘international’ instruments
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(EuroQoL and WHOQoL) that refl ects 
the overt need for the measurement 
and comparison of QoL across national 
boundaries by questionnaires that are 
not culturally specifi c.
Discussion
The use of a sampling technique across 
fi ve year time periods seemed to provide 
a reasonably consistent pattern of 
trends across a very large number of 
publications. These trends, of course, 
have to be set against the overall growth 
of QoL papers (see Figure 1) such that 
the sample of 50 papers from 2005, say, is 
drawn from a much larger population of 
papers. Nevertheless, some broad themes 
can be identifi ed despite the imprecision 
of some of the estimates of proportions of 
types of paper.
There was both a rhetorical and 
material genealogy of QoL standards that 
operated iteratively. QoL measurement 
started off with an advocacy period that 
lasted nearly 20 years. This involved 
promoting the concept of QoL to a naïve 
medical audience; towards the end of 
the period, however, it was often diffi cult 
to distinguish between QoL promotion 
and conceptual dissection as one 
form mutated into the other. The brief 
fl owering of ethical studies in the late 
1980s may mirror the concurrent growth 
in medical ethics but its absence in the 
later periods may refl ect more on the 
dominance of empirical studies.
As advocacy declined a period 
of methodological development 
emerged, no doubt refl ecting the 
general acceptance that QoL was worth 
measuring and could be measured with 
appropriate questionnaires—though 
discussion about what it really was 
continued at least until 2000. Perhaps the 
appearance of ‘head-to-head’ papers in 
2000 also marks another watershed: the 
task of methodological research is not 
only to devise and test new instruments 
but also to destroy redundant ones so 
only the best survive.
Outcome studies followed closely on 
from the methodological development 
phase.  These were dominated at fi rst 
by simple descriptions of the QoL held 
by many different populations—as if 
researchers were both mapping the 
QoL landscape of medicine and playing 
with their powerful new device. But its 
increasing role was most pronounced 
in comparative work, in particular in 
evaluative studies that tried to discover 
whether new medical therapies and 
technologies really ‘worked’. It is this 
role that dominates the use of QoL 
instruments in the new century.
By analysing published papers to 
discover the stages through which an 
instrument passes through—from initial 
conceptualisation to widespread us—
the institutional and political context in 
which QoL developed and was applied is 
ignored. Even so, the discourse captured 
in these papers both supports and refl ects 
those wider social contexts. On the one 
hand, the drive towards the evaluation 
of health care and assessments of 
comparative effectiveness which has 
been such an important feature of health 
care delivery over the last few decades, 
needed instruments such as QoL as their 
endpoints; in that sense QoL stabilisation 
was one of the key resources for evaluation 
policies. On the other hand, the increased 
institutional demand for viable endpoints 
in pursuit of effi cient health care (such as 
the wide deployment of QALYS—quality 
adjusted life years—as measures of health 
care outcome) has underpinned the 
maturation of QoL measurement and the 
further proliferation of papers using the 
construct. While there has been no direct 
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exploration of the wider institutional 
context in which QoL was embedded, the 
discourse described in this paper has acted 
as both a resource and a manifestation of 
activities in a wider social world beyond 
the documentary trail analysed here. The 
stabilisation of QoL through its successful 
operationalisation and extensive 
application created both the potential for 
new worlds of clinical practice and health 
policies but also constraints on those 
worlds. Though QoL has only recently 
been ‘invented’ it cannot be ‘de-invented’; 
once it achieved a certain level of 
conceptual clarifi cation and legitimacy—
together with a wealth of standardised 
instruments and accumulated scores—it 
both described and constructed a world 
that was impervious to challenge. It 
provided new goals for modern medicine, 
underpinning new disciplines such as 
palliative care and informing decision-
making in everyday clinical practice.
The process of stabilising QoL 
described here echoes previous work 
in the sociology of science which has 
its origin in Fleck’s (1979) seminal 
work (originally published in 1935) on 
how scientifi c ‘facts’ are constructed. 
Subsequent studies, such as Latour and 
Woolgar’s (1979) analysis of how a specifi c 
peptide was constructed as a scientifi c 
fact, have described the process of 
stabilisation in closer detail; indeed, more 
generally the scientifi c activity through 
which support is recruited to make 
tentative ideas into hard facts has been 
described by Latour (1987) as ‘science-in-
action’. Yet to some extent the imprecision 
of concepts—and their resistance to 
stabilisation—is also an important part 
of the scientifi c process. Rorty (1989), 
for example, suggested that scientifi c 
concepts expressed as metaphors had 
much greater creative power than when 
their meaning eventually became fi xed 
through a process of ‘literalisation’. 
Equally, in her study of the development 
of immunology, Lowy (1992) showed how 
‘loose concepts’ at the boundaries of a 
scientifi c explanatory framework could 
facilitate stabilisation in the more central 
disciplinary core. QoL, however, offers 
another example of how stabilisation 
works.
In the mid 1970s QoL was only an idea, a 
rhetorical fl ourish (which mainly emerged 
outside of medicine) that identifi ed 
a potential new outcome for medical 
work; thirty years later that construct 
has materialised as a ‘real’ phenomenon 
through the repeated application of 
QoL instruments that establishes and 
re-establishes that everyone has this 
‘thing’ that a few decades earlier was 
not even a gleam in the doctor’s eye. 
Yet despite this stabilisation there are 
key elements of QoL which remain 
contentious as there is no consensus 
as to what constitutes a ‘good quality of 
life’ and the continuing proliferation of 
instruments attests to its frequent lack 
of standardisation. In that sense QoL is 
a ‘loose concept’; yet it is also a ‘fact’ in 
that it can express in precise numbers 
the state of a patient’s well-being. It is 
the tension between contested concept 
and fi xed measurement that seems to 
characterise QoL: broad agreement that 
it can now join life, death and illness as 
one of the central components of the 
Western medical paradigm, yet, at the 
same time, no consensus as to its precise 
meaning. And while it continues to be 
fi xed as a scientifi c fact by a plethora of 
measurement instruments, there are 
already indications that the underlying 
construct may continue to shift.  Recent 
debates about the importance of well-
being and happiness as a goal for clinical 
(and other) interventions may refl ect a 
new phase of the development of the QoL 
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construct, perhaps to be renamed but 
to be stabilised by the application of yet 
more instruments and measures.
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